Anteris Technologies Ltd. (AU:AVR) has released an update.
Anteris Technologies Ltd has announced the successful completion of a complex ‘Valve-in-Valve-in-Valve’ procedure using their DurAVR™ valve at the Karolinska University Hospital in Sweden. This medical breakthrough provided a life-enhancing solution for a patient who was deemed unsuitable for any other surgical or commercial transcatheter aortic valve replacement (TAVR) options. Anteris’s biomimetic DurAVR™ valve continues to show promise for patients with native aortic stenosis and those who require subsequent valve replacements, positioning the company as an innovator in the structural heart disease market.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
